These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 8226427)

  • 21. In-vitro pharmacodynamic studies of piperacillin/tazobactam with gentamicin and ciprofloxacin.
    Gould IM; Milne K
    J Antimicrob Chemother; 1997 Jan; 39(1):53-61. PubMed ID: 9044028
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against over 2,000 clinical isolates from 22 medical centers in Japan. Japan Antimicrobial Resistance Study Group.
    Yamaguchi K; Mathai D; Biedenbach DJ; Lewis MT; Gales AC; Jones RN
    Diagn Microbiol Infect Dis; 1999 Jun; 34(2):123-34. PubMed ID: 10354863
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative in-vitro activity of piperacillin and piperacillin plus tazobactam towards beta-lactamase producing clinical isolates.
    Stefani S; Castiglia P; Maida A; Muresu E; Mezzatesta ML; Nicoletti G
    J Chemother; 1990 Oct; 2(5):295-9. PubMed ID: 1965317
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activity of ceftaroline, ceftazidime-avibactam, and comparators against Gram-positive and -negative organisms in China: the 2018 results from the ATLAS program.
    Jia P; Zhu Y; Zhang H; Cheng B; Guo P; Xu Y; Yang Q
    BMC Microbiol; 2022 Oct; 22(1):234. PubMed ID: 36182895
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative antimicrobial activity of piperacillin-tazobactam tested against more than 5000 recent clinical isolates from five medical centers. A reevaluation after five years.
    Marshall SA; Aldridge KE; Allen SD; Fuchs PC; Gerlach EH; Jones RN
    Diagn Microbiol Infect Dis; 1995 Mar; 21(3):153-68. PubMed ID: 7648836
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The activity of piperacillin/tazobactam against clinical isolates collected in 20 UK centres and the design of a disc test for susceptibility testing.
    Reeves DS; Holt HA; Bywater MJ; MacGowan AP
    J Antimicrob Chemother; 1993 Jul; 32(1):51-61. PubMed ID: 8226417
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibacterial activity of piperacillin and tazobactam against beta-lactamase-producing clinical isolates.
    Cullmann W; Stieglitz M
    Chemotherapy; 1990; 36(5):356-64. PubMed ID: 2170081
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam.
    Kuck NA; Jacobus NV; Petersen PJ; Weiss WJ; Testa RT
    Antimicrob Agents Chemother; 1989 Nov; 33(11):1964-9. PubMed ID: 2558615
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Behaviour of beta-lactamase-positive and -negative Staphylococcus aureus isolates in susceptibility tests with piperacillin/tazobactam and other beta-lactam/beta-lactamase inhibitor combinations.
    Bonfiglio G; Livermore DM
    J Antimicrob Chemother; 1993 Sep; 32(3):431-44. PubMed ID: 8262865
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp. from intensive care units in Europe.
    Livermore DM; Yuan M
    J Antimicrob Chemother; 1996 Sep; 38(3):409-24. PubMed ID: 8889716
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antimicrobial activities of piperacillin alone and in combination with tazobactam against beta-lactamase-producing bacteria.
    Chang SC; Hsu LY; Luh KT; Hsieh WC
    J Formos Med Assoc; 1991 Oct; 90(10):947-52. PubMed ID: 1685175
    [TBL] [Abstract][Full Text] [Related]  

  • 32. National survey of the in vitro spectrum of piperacillin-tazobactam tested against more than 40,000 aerobic clinical isolates from 236 medical centers.
    Baron EJ; Jones RN
    Diagn Microbiol Infect Dis; 1995 Mar; 21(3):141-51. PubMed ID: 7648835
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study.
    Joly-Guillou ML; Kempf M; Cavallo JD; Chomarat M; Dubreuil L; Maugein J; Muller-Serieys C; Roussel-Delvallez M
    BMC Infect Dis; 2010 Mar; 10():72. PubMed ID: 20298555
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bactericidal activity of ertapenem against major intra-abdominal pathogens.
    Borbone S; Cascone C; Santagati M; Mezzatesta ML; Stefani S
    Int J Antimicrob Agents; 2006 Nov; 28(5):396-401. PubMed ID: 17045463
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In-vitro activity of piperacillin and tazobactam combination against clinically significant bacteria.
    Obi CL; Makandiramba B; Robertson V; Tswana SA; Moyo SR; Nziramasanga P
    East Afr Med J; 1998 Mar; 75(3):162-5. PubMed ID: 9640815
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Evaluation of in vitro susceptibility of hospital bacterial isolates to piperacillin and tazocin (piperacillin/tazobactam].
    Birawska I; Fuchs J; Szulakowska E
    Med Dosw Mikrobiol; 1998; 50(1-2):41-6. PubMed ID: 9857612
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative in vitro activity of piperacillin combined with the beta-lactamase inhibitor tazobactam (YTR 830).
    Eliopoulos GM; Klimm K; Ferraro MJ; Jacoby GA; Moellering RC
    Diagn Microbiol Infect Dis; 1989; 12(6):481-8. PubMed ID: 2560420
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prediction of piperacillin-tazobactam susceptibility among Enterobacteriaceae, Pseudomonas aeruginosa, and other bacteria using ticarcillin-clavulanic acid, ceftazidime, and other broad-spectrum antimicrobial in vitro test results.
    Jones RN; Sutton LD; Cantrell HF; Lankford RB
    Diagn Microbiol Infect Dis; 1994 Nov; 20(3):143-9. PubMed ID: 7874881
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN; Sader HS; Fritsche TR; Pottumarthy S
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative in-vitro activity of piperacillin-tazobactam against recent clinical isolates, a Dutch national multicentre study.
    Stobberingh EE; Maclaren DM; Schmitz PI
    J Antimicrob Chemother; 1994 Nov; 34(5):777-83. PubMed ID: 7706173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.